Released On
February 13, 2025
Expires On
February 13, 2026
Media Type
Internet
Completion Time
15 minutes
Specialty
Hematology & Oncology, Pathology, Pharmacy, Pulmonology
Topics
Lung Cancer
Acknowledgement
This independent medical education program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Credit Available
- Physicians — maximum of 0.25 AMA PRA Category 1 Credit™
- Nurses — 0.25 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of oncologists, pathologists and those treating patients with NSCLC worldwide.
Program Overview
This activity will help you learn how to implement effective multidisciplinary collaboration to improve care for patients with biomarker-positive NSCLC.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select appropriate biomarker tests to inform treatment selection for patients with NSCLC
- Integrate new clinical data on targeted therapies into clinical practice to create individualized treatment plans for patients with biomarker-positive NSCLC
- Utilize educational tools and resources to help patients engage in a shared decision-making approach when selecting a management strategy
- Formulate comprehensive management plans for patients that integrate effective multidisciplinary collaboration
Faculty
Prof Nicolas Girard
Nicolas Girard is a pneumologist specializing in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. He is domain leader for rare thoracic cancers for the European Reference Network EURACAN. Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. He is Professor of Respiratory Medicine at Versailles Saint Quentin University, Paris Saclay Campus. He is the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Department at Institut Curie in Paris. Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.
Accreditation Statement
This activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Springer Healthcare IME. PIM is committed to ensuring that all jointly provided activities are planned and implemented in accordance with the requirements of the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses Credentialing Center Commission on Accreditation (ANCC), and the Accreditation Council for Pharmacy Education (ACPE), or other accrediting body, as appropriate to the type of credit to be provided by the activity.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The Springer Healthcare IME planners and others have nothing to disclose.
All relevant financial relationships have been mitigated.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.
Disclosure of Conflicts of Interest
Prof Nicolas Girard:
- Research grants/support from: Abbvie, Amgen, AstraZeneca, Beigene, Boeringer Ingelheim, Bristol Myers Squib, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Sanofi, Sivan.
- Consultative services for: Abbvie, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Sharpe & Dohme, Mirati, Novartis, Pfizer, Pierre Fabre, Sanofi, Sivan Takeda.
- Participation on a data safety monitoring board for Hoffmann-La Roche.
- Employment of a family member with AstraZeneca.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Complete the activity module
- Fill out the short evaluation form at the end of the module. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]